Two Targets, One Mission: Optimizing Bispecific Antibody Use in Non-Hodgkin Lymphoma

A satellite symposium broadcast at ASHP Midyear 2025.

11:30 AM PT (2:30 PM ET)

Room: South Pacific B, Lower Level

Stream Link: https://event.arraylive.com/app/login/e5a20d05-4005-41d0-8bfe-fffc11bd125b/virtualattendee

Program Description

While chemoimmunotherapy has improved outcomes for patients with non-Hodgkin lymphoma (NHL), a significant number of patients relapse or have refractory disease. In the past several years, bispecific antibodies (BsAbs) have emerged as an important therapeutic option in NHL, with trials continuing to explore their use in earlier lines of treatment. As new BsAb therapies receive FDA approval and are incorporated into treatment guidelines, oncology pharmacists are crucial in navigating the complexities of their safe and effective use. This program will provide a comprehensive overview of BsAbs used in NHL, including their unique mechanism of action, therapeutic targets, and clinical evidence in key NHL subtypes. Expert faculty will share insights on the latest guideline-directed use of BsAbs, including in combination regimens and for patients ineligible for CAR-T cell therapy. Additionally, panelists will lead a case-based discussion focusing on real-world challenges and pharmacist-driven solutions for BsAb integration, including important topics such as therapy sequencing, site-of-care coordination, and essential elements of patient education.

Target audience: Health system pharmacists, Oncology pharmacists

Type of activity: Application
Release date: December 8, 2025
Expiration date: February 8, 2026

Time to complete activity: 1.5 hours

Learner level: Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the role of bispecific antibodies (BsAbs) in the management of non-Hodgkin lymphoma (NHL) based on emerging clinical data
• Apply key pharmacologic, clinical, and logistical factors to guide BsAb selection in NHL
• Analyze expert approaches to adverse effect prevention and intervention in the context of BsAb therapies
• Explore best practices for managing operational challenges related to BsAb implementation, including workflow design, resource utilization, and targeted education for patients and health care providers

Accreditation Information

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Each CE broadcast/symposium is approved for 1.5 contact hours (0.15 CEU) of application-based credit.

Obtaining Credit

All participants who attended the live virtual broadcast need to log on to their Pharmacy Times Continuing Education™ account on www.pharmacytimes.org to complete an online evaluation form and request their credit. Instructions on receiving credit will be provided the day of the event.